이혁재

이혁재, listed as senior executive, appears in our data through filings on 인바이오 shares, published by DART (FSS). In total, 26 filings cover trades dated from 13 April 2021 to 10 August 2026.

Purchases make up the whole of the open-market record (26 purchases, €5,940). The amount is not disclosed for 23 filings. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. In 2026 alone, the filings show 9 purchases and no sales.

In size, the median ticket on the buying side is €2,071. Measured against the company's value, the median purchase equals 0.016% of market capitalisation, across 3 purchases where it is known. Across 18 purchases, this insider has always bought alone, with no colleague buying within 30 days.

The latest filing, published on 10 August 2026, reports an open-market purchase in 인바이오. Between a trade and the moment it shows up on DART (FSS), the median delay is 9 days. Until a filing is published, the market cannot know about the trade. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.